全球连续血糖监测设备市场规模、份额、成长分析（按组件、最终用途）- 2024-2031 年产业预测

Global Continuous Glucose Monitoring Devices Market Size, Share, Growth Analysis, By Component(Transmitters, Sensors), By End-Use(Hospitals, Home Care) - Industry Forecast 2024-2031

出版日期: 2024年03月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年，全球连续血糖监测设备市场规模将为80亿美元，从2023年的84亿美元成长到2031年的124.1亿美元，预测期内（2024-2031年）预计复合年增长率为5%。

糖尿病患者数量的增加和连续血糖监测（CGM）设备的普及正在推动市场发展。众所周知，这些设备侵入性较小，并且更容易管理糖尿病。它还可以检测血糖值的大幅变化并防止危险的下降。由于感测器的存在，CGM 设备会在不同时间检查血糖值。收集的资料透过无线方式发送到软体，帮助糖尿病患者更好地了解并更有效地管理他们的病情。因吸烟、过重、缺乏运动、高血压和高胆固醇等常见因素都会使糖尿病恶化。根据国际糖尿病联盟的数据，2022年约有5.366亿人患有糖尿病，预计2030年这一数字将增加至6.428亿，2045年将增加至7.837亿。 CGM 设备还提供有关您吃什么、如何服药、您的活跃程度以及其他健康状况的资讯。数位工具使製造 CGM 设备的公司更容易与糖尿病患者建立联繫。市场上有许多应用程式使用 CGM 设备中的资料来了解未来可能发生的情况并提案生活方式的改变。雅培 (Abbott)、Dexcom 和美敦力 (Medtronic) 等公司在糖尿病产品上赚了更多钱，因为在 COVID-19 大流行期间有很多人需要这些产品。检查血糖值的设备已被证明有助于控制血糖水平，并可以帮助糖尿病患者更好地控制病情。在 COVID-19 大流行期间，世界各地的许多政府开始为这些设备付费，因此更多的糖尿病患者和医疗保健提供者开始使用它们。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

Abbott（USA）
Dexcom（USA）
Medtronic（Ireland）
Roche Diagnostics（Switzerland）
Senseonics Holdings（USA）
Lifespan（South Korea）
Ascensia Diabetes Care（Switzerland）
Nemaura Medical（UK）
Ypsomed（Switzerland）
Glysens（USA）
Tandem Diabetes Care（USA）
MedAngel（Belgium）
Bigfoot Biomedical（USA）
Novo Nordisk（Denmark）
Sensionics（USA）
MicroPort（China）
Insulet Corporation（USA）
GluSense（Israel）
DarioHealth（USA）
Admetsys（USA）

简介目录

Product Code: SQMIG35A2568

The Global Continuous Glucose Monitoring Devices Market size was valued at USD 8 billion in 2022 and is poised to grow from USD 8.40 billion in 2023 to USD 12.41 billion by 2031, growing at a CAGR of 5% in the forecast period (2024- 2031).

The increasing number of people with diabetes and the growing use of continuous glucose monitoring (CGM) devices are pushing the market forward. These devices are known for being less invasive and making it easier to manage diabetes. They can also detect big changes in blood sugar levels and prevent dangerous drops. With a sensor, CGM devices check blood sugar levels at different times. The data they collect is sent wirelessly to software that helps people with diabetes understand their condition better and manage it more effectively. Common things like smoking, being overweight, not being active, high blood pressure, and high cholesterol levels can make diabetes worse. According to the International Diabetes Federation, about 536.6 million people had diabetes in 2022, and this number is expected to go up to 642.8 million by 2030 and 783.7 million by 2045. CGM devices also give information about what people eat, how they take medicine, how active they are, and other health conditions. Digital tools have made it easier for companies that make CGM devices to connect with people with diabetes. There are lots of apps on the market that use data from CGM devices to see what might happen in the future and suggest changes to lifestyle. Companies like Abbott, Dexcom, and Medtronic have made a lot more money from their diabetes products because more people wanted them during the COVID-19 pandemic. Devices that check blood sugar levels have been shown to help control sugar levels and might help people with diabetes manage their condition better. Many governments around the world started paying for these devices during the COVID-19 pandemic, so more people with diabetes and healthcare providers started using them.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Continuous Glucose Monitoring Devices Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Continuous Glucose Monitoring Devices Market Segmental Analysis

Global Continuous Glucose Monitoring Devices Market is segmented on the basis of Component, End - User, Region. By Component, the market is segmented Transmitters, Sensors, Receivers. By End - user, the market is segmented into Hospitals, Home Care, Others. By Region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Continuous Glucose Monitoring Devices Market

The growing number of people with diabetes worldwide is a big reason why there's a need for better ways to check and manage it, like continuous glucose monitoring devices.

Restraints in the Global Continuous Glucose Monitoring Devices Market

Continuous glucose monitoring devices are now being combined with digital health platforms, which makes it easy for users to keep track of and manage their data together with other health information.

Market Trends of the Global Continuous Glucose Monitoring Devices Market

More and more, Continuous Glucose Monitoring Devices systems are using Industry 4.0 technologies like sensors, internet connection, and predictive maintenance. This helps to watch them in real-time and make them work better.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Continuous Glucose Monitoring Devices Market by Component

Market Overview
Transmitters
Sensors
Receivers

Global Continuous Glucose Monitoring Devices Market by End-Use

Market Overview
Hospitals
Home Care
Others

Global Continuous Glucose Monitoring Devices Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Abbott (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dexcom (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Senseonics Holdings (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lifespan (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ascensia Diabetes Care (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nemaura Medical (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glysens (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tandem Diabetes Care (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MedAngel (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bigfoot Biomedical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sensionics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MicroPort (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insulet Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GluSense (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DarioHealth (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Admetsys (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments